User profiles for Neel Jasani
 | Neel JasaniPhD candidate Verified email at moffitt.org Cited by 78 |
[HTML][HTML] A MAPK/miR-29 axis suppresses melanoma by targeting MAFG and MYBL2
Simple Summary The miR-29 family is subjected to complex regulation by tumor suppressors
and oncogenes and has tumor suppressive potential in several cancers. We demonstrate …
and oncogenes and has tumor suppressive potential in several cancers. We demonstrate …
Omega‐3 fatty acid grafted PAMAM‐Paclitaxel conjugate exhibits enhanced anticancer activity in upper gastrointestinal cancer cells
Upper Gastrointestinal Cancers (UGCs) are a leading cause of cancer‐related deaths
worldwide. Paclitaxel (PTX) is frequently used for the treatment of UGCs; however, low …
worldwide. Paclitaxel (PTX) is frequently used for the treatment of UGCs; however, low …
A Versatile ES Cell–Based Melanoma Mouse Modeling Platform
The cumbersome and time-consuming process of generating new mouse strains and multiallelic
experimental animals often hinders the use of genetically engineered mouse models (…
experimental animals often hinders the use of genetically engineered mouse models (…
PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis
PTEN suppresses melanoma predominantly through its lipid phosphatase function, which
when lost, elevates FRA1 levels through AKT/mTOR signaling to promote several aspects of …
when lost, elevates FRA1 levels through AKT/mTOR signaling to promote several aspects of …
Gain of chromosome 1q perturbs a competitive endogenous RNA network to promote melanoma metastasis
The function of CEP170, NUCKS1 , and ZC3H11A mRNAs as competitive endogenous
RNAs that sequester tumor suppressor microRNAs underlies the oncogenic activity of …
RNAs that sequester tumor suppressor microRNAs underlies the oncogenic activity of …
The lipid phosphatase activity of PTEN dampens FRA1 expression via AKT/mTOR signaling to suppress melanoma
PTEN opposes AKT/mTOR pathway activation via its lipid phosphatase activity. While PTEN
is frequently inactivated in melanoma, AKT- or mTOR-targeted therapies have so far yielded …
is frequently inactivated in melanoma, AKT- or mTOR-targeted therapies have so far yielded …
MAPK-mediated PHGDH induction is essential for melanoma formation and represents an actionable vulnerability
Overexpression of PHGDH, the rate-limiting enzyme in the serine synthesis pathway, promotes
melanomagenesis, melanoma cell proliferation, and survival of metastases in serine-low …
melanomagenesis, melanoma cell proliferation, and survival of metastases in serine-low …
Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent
Introduction: Eukaryotic translation initiation factor 4E (eIF4E) is a master regulator that
controls translation of mRNA in mammalian cells. eIF4E is a proto-oncogene that promotes …
controls translation of mRNA in mammalian cells. eIF4E is a proto-oncogene that promotes …
Long non-coding RNAs in melanoma development and biology
O Vera, N Jasani, FA Karreth - Proceedings of the Singapore …, 2020 - World Scientific
Melanoma is the most aggressive and deadly type of skin cancer and presents a major
clinical challenge due to its ability to rapidly metastasize and become resistant to immune and …
clinical challenge due to its ability to rapidly metastasize and become resistant to immune and …
BRAF-mediated PHGDH induction establishes a metabolic vulnerability in melanoma
Phosphoglycerate Dehydrogenase (PHGDH) gene, encoding the rate limiting enzyme of the
serine synthesis pathway, is located at chromosome locus 1p12 and frequently amplified in …
serine synthesis pathway, is located at chromosome locus 1p12 and frequently amplified in …